106 related articles for article (PubMed ID: 25441945)
21. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
[TBL] [Abstract][Full Text] [Related]
22. Screening of a novel free fatty acid receptor 1 (FFAR1) agonist peptide by phage display and machine learning based-amino acid substitution.
Yoshioka K; Yamashita H; Shimizu K; Shimomura S; Shibata T; Miyazaki JI; Honda H
Biochem Biophys Res Commun; 2021 Apr; 550():177-183. PubMed ID: 33706101
[TBL] [Abstract][Full Text] [Related]
23. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.
Li Z; Zhou Z; Zhang L
Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391
[No Abstract] [Full Text] [Related]
24. Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells.
Seto-Young D; Avtanski D; Strizhevsky M; Parikh G; Patel P; Kaplun J; Holcomb K; Rosenwaks Z; Poretsky L
J Clin Endocrinol Metab; 2007 Jun; 92(6):2232-9. PubMed ID: 17374711
[TBL] [Abstract][Full Text] [Related]
25. Novel ligands that target the mitochondrial membrane protein mitoNEET.
Bieganski RM; Yarmush ML
J Mol Graph Model; 2011 Jun; 29(7):965-73. PubMed ID: 21531159
[TBL] [Abstract][Full Text] [Related]
26. Mechanistic Studies on the Stereoselectivity of FFAR1 Modulators.
Teng D; Zhou Y; Tang Y; Liu G; Tu Y
J Chem Inf Model; 2022 Aug; 62(15):3664-3675. PubMed ID: 35877470
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of bovine opsin bound to G-protein fragments.
Sugihara M; Suwa M; Bondar AN
J Struct Biol; 2014 Oct; 188(1):79-86. PubMed ID: 25138898
[TBL] [Abstract][Full Text] [Related]
28. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
Sheu SH; Kaya T; Waxman DJ; Vajda S
Biochemistry; 2005 Feb; 44(4):1193-209. PubMed ID: 15667213
[TBL] [Abstract][Full Text] [Related]
29. Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1.
Lückmann M; Trauelsen M; Bentsen MA; Nissen TAD; Martins J; Fallah Z; Nygaard MM; Papaleo E; Lindorff-Larsen K; Schwartz TW; Frimurer TM
Proc Natl Acad Sci U S A; 2019 Apr; 116(14):7123-7128. PubMed ID: 30872479
[TBL] [Abstract][Full Text] [Related]
30. Free fatty acid receptor 1 as a novel therapeutic target for type 2 diabetes mellitus-current status.
Eleazu C; Charles A; Eleazu K; Achi N
Chem Biol Interact; 2018 Jun; 289():32-39. PubMed ID: 29704509
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
[TBL] [Abstract][Full Text] [Related]
32. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
33. Stimulation of insulin secretion by acetylenic fatty acids in insulinoma MIN6 cells through FFAR1.
Nishino K; Uesugi H; Hirasawa A; Ohtera A; Miyamae Y; Neffati M; Isoda H; Kambe T; Masuda S; Irie K; Nagao M
Biochem Biophys Res Commun; 2020 Jan; 522(1):68-73. PubMed ID: 31740001
[TBL] [Abstract][Full Text] [Related]
34. Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.
Saha S; Chan DS; Lee CY; Wong W; New LS; Chui WK; Yap CW; Chan EC; Ho HK
Eur J Pharmacol; 2012 Dec; 697(1-3):13-23. PubMed ID: 23041271
[TBL] [Abstract][Full Text] [Related]
35. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.
Ye F; Zhang ZS; Luo HB; Shen JH; Chen KX; Shen X; Jiang HL
Chembiochem; 2006 Jan; 7(1):74-82. PubMed ID: 16317783
[TBL] [Abstract][Full Text] [Related]
36. Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation.
Sum CS; Tikhonova IG; Costanzi S; Gershengorn MC
J Biol Chem; 2009 Feb; 284(6):3529-36. PubMed ID: 19068482
[TBL] [Abstract][Full Text] [Related]
37. A Selectivity Study of FFAR4/FFAR1 Agonists by Molecular Modeling.
Zhang X; Sun H; Wen X; Yuan H
J Chem Inf Model; 2019 Oct; 59(10):4467-4474. PubMed ID: 31580060
[TBL] [Abstract][Full Text] [Related]
38. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
Li Z; Xu X; Huang W; Qian H
Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
[TBL] [Abstract][Full Text] [Related]
39. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.
Ferruzzi P; Ceni E; Tarocchi M; Grappone C; Milani S; Galli A; Fiorelli G; Serio M; Mannelli M
J Clin Endocrinol Metab; 2005 Mar; 90(3):1332-9. PubMed ID: 15585569
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
